Literature DB >> 18343584

Phosphorylation of tau and alpha-synuclein in synaptic-enriched fractions of the frontal cortex in Alzheimer's disease, and in Parkinson's disease and related alpha-synucleinopathies.

G Muntané1, E Dalfó, A Martinez, I Ferrer.   

Abstract

Phosphorylation of tau and phosphorylation of alpha-synuclein are crucial abnormalities in Alzheimer's disease (AD) and alpha-synucleinopathies (Parkinson's disease: PD, and dementia with Lewy bodies: DLB), respectively. The presence and distribution of phospho-tau were examined by sub-fractionation, gel electrophoresis and Western blotting in the frontal cortex of cases with AD at different stages of disease progression, PD, DLB pure form and common form, and in age-matched controls. Phospho-tauSer396 has been found in synaptic-enriched fractions in AD frontal cortex at entorhinal/transentorhinal, limbic and neocortical stages, thus indicating early tau phosphorylation at the synapses in AD before the occurrence of neurofibrillary tangles in the frontal cortex. Phospho-tauSer396 is also found in synaptic-enriched fractions in the frontal cortex in PD and DLB pure and common forms, thus indicating increased tau phosphorylation at the synapses in these alpha-synucleinopathies. Densitometric studies show between 20% and 40% phospho-tauSer396, in relation with tau-13, in synaptic-enriched fractions of the frontal cortex in AD stages I-III, and in PD and DLB. The percentage reaches about 95% in AD stage V and DLB common form. Yet tau phosphorylation characteristic of neurofibrillary tangles, as revealed with the AT8 antibody, is found in the synaptic fractions of the frontal cortex only at advanced stages of AD. Increased phosphorylated alpha-synucleinSer129 levels are observed in the synaptic-enriched fractions of the frontal cortex in PD and DLB pure and common forms, and in advanced stages of AD. Since tau-hyperphosphorylation has implications in microtubule assembly, and phosphorylation of alpha-synuclein at Ser129 favors alpha-synuclein aggregation, it can be suggested that synapses are targets of abnormal tau and alpha-synuclein phosphorylation in both groups of diseases. Tau phosphorylation at Ser396 has also been found in synaptic-enriched fractions in 12-month-old transgenic mice bearing the A53T alpha-synuclein mutation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18343584     DOI: 10.1016/j.neuroscience.2008.01.030

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  57 in total

1.  GSK-3β dysregulation contributes to parkinson's-like pathophysiology with associated region-specific phosphorylation and accumulation of tau and α-synuclein.

Authors:  J J Credle; J L George; J Wills; V Duka; K Shah; Y-C Lee; O Rodriguez; T Simkins; M Winter; D Moechars; T Steckler; J Goudreau; D I Finkelstein; A Sidhu
Journal:  Cell Death Differ       Date:  2014-11-14       Impact factor: 15.828

2.  An evaluation of the impact of MAPT, SNCA and APOE on the burden of Alzheimer's and Lewy body pathology.

Authors:  Christian Wider; Owen A Ross; Kenya Nishioka; Michael G Heckman; Carles Vilariño-Güell; Barbara Jasinska-Myga; Nilufer Erketin-Taner; Rosa Rademakers; Neill R Graff-Radford; Deborah C Mash; Spiridon Papapetropoulos; Ranjan Duara; Hirotake Uchikado; Zbigniew K Wszolek; Matthew J Farrer; Dennis W Dickson
Journal:  J Neurol Neurosurg Psychiatry       Date:  2012-01-30       Impact factor: 10.154

Review 3.  Rodent models and contemporary molecular techniques: notable feats yet incomplete explanations of Parkinson's disease pathogenesis.

Authors:  Sharawan Yadav; Anubhuti Dixit; Sonal Agrawal; Ashish Singh; Garima Srivastava; Anand Kumar Singh; Pramod Kumar Srivastava; Om Prakash; Mahendra Pratap Singh
Journal:  Mol Neurobiol       Date:  2012-06-27       Impact factor: 5.590

4.  Therapy for Alzheimer's Disease: How Effective are Current Treatments?

Authors:  Krista L Lanctôt; Ryan D Rajaram; Nathan Herrmann
Journal:  Ther Adv Neurol Disord       Date:  2009-05       Impact factor: 6.570

5.  Simultaneous characterization of glyco- and phosphoproteomes of mouse brain membrane proteome with electrostatic repulsion hydrophilic interaction chromatography.

Authors:  Huoming Zhang; Tiannan Guo; Xin Li; Arnab Datta; Jung Eun Park; Jie Yang; Sai Kiang Lim; James P Tam; Siu Kwan Sze
Journal:  Mol Cell Proteomics       Date:  2010-01-04       Impact factor: 5.911

6.  Alpha-synuclein immunopositive aggregates in the myenteric plexus of the aging Fischer 344 rat.

Authors:  Robert J Phillips; Gary C Walter; Brittany E Ringer; Katherine M Higgs; Terry L Powley
Journal:  Exp Neurol       Date:  2009-08-05       Impact factor: 5.330

7.  Biochemical increase in phosphorylated alpha-synuclein precedes histopathology of Lewy-type synucleinopathies.

Authors:  Lih-Fen Lue; Douglas G Walker; Charles H Adler; Holly Shill; Hung Tran; Haruhiko Akiyama; Lucia I Sue; John Caviness; Marwan N Sabbagh; Thomas G Beach
Journal:  Brain Pathol       Date:  2012-04-12       Impact factor: 6.508

8.  Magnetite nanoparticles coated with mercaptosuccinic acid-modified mesoporous titania as a hydrophilic sorbent for glycopeptides and phosphopeptides prior to their quantitation by LC-MS/MS.

Authors:  Nianrong Sun; Jiawen Wang; Jizong Yao; Hemei Chen; Chunhui Deng
Journal:  Mikrochim Acta       Date:  2019-02-04       Impact factor: 5.833

Review 9.  Interactions Between α-Synuclein and Tau Protein: Implications to Neurodegenerative Disorders.

Authors:  Xuling Li; Simon James; Peng Lei
Journal:  J Mol Neurosci       Date:  2016-09-15       Impact factor: 3.444

Review 10.  Parkinson's disease and parkinsonism: neuropathology.

Authors:  Dennis W Dickson
Journal:  Cold Spring Harb Perspect Med       Date:  2012-08-01       Impact factor: 6.915

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.